What are the investment strengths of Propanc Biopharma Inc (PPCB)?

Trading at 0.49x book (14.4M equity vs 7M market cap) with minimal debt (0.05 D/E) - optionality on pipeline success at distressed valuation Positive working capital of 5.2M provides short-term buffer; biotech binary outcomes can generate 10x+ returns on clinical success

What are the investment risks for Propanc Biopharma Inc (PPCB)?

Near-zero R&D (222K) suggests no meaningful clinical progress - burning cash on G&A without advancing pipeline toward value-creating milestones Structural dilution trap: 3.3M raised barely covers 2.1M burn - each financing round destroys shareholder value at sub-book prices

Propanc Biopharma Inc

PPCB

—

Build a strategy around PPCB

Propanc Biopharma Inc AI Insights

Informational only. Not investment advice.

As of 2026-01-02

Snapshot

Zero revenue TTM with -63.4M net loss - pure cash burn pre-clinical biotech with 602K cash vs 2.1M annual burn rate (~3 months runway)[Cash and Equivalents / Free Cash Flow TTM]
Raised 3.3M via stock issuance TTM - dilution-funded survival with shares outstanding at 12.3M, trading at 0.49x book value[Issuance of Capital Stock / P/B Ratio]
R&D spend only 222K TTM (<1% of operating expenses) - minimal pipeline investment despite being development-stage[Research and Development TTM]

Watch Triggers

Cash and Equivalents: Falls below 300K or no financing announced within 90 days — Going concern risk - inability to fund operations triggers delisting/bankruptcy
Research and Development TTM: Increases >500K with clinical milestone announcement — Would signal actual pipeline advancement vs pure cash burn
Shares Outstanding: Increases >50% from 12.3M baseline — Massive dilution would confirm value destruction thesis

Bull Case

Trading at 0.49x book (14.4M equity vs 7M market cap) with minimal debt (0.05 D/E) - optionality on pipeline success at distressed valuation

P/B RatioDebt to EquityTangible Book Value

Positive working capital of 5.2M provides short-term buffer; biotech binary outcomes can generate 10x+ returns on clinical success

Working CapitalTotal Equity

Bear Case

Near-zero R&D (222K) suggests no meaningful clinical progress - burning cash on G&A without advancing pipeline toward value-creating milestones

Research and Development TTMOperating Expense TTM

Structural dilution trap: 3.3M raised barely covers 2.1M burn - each financing round destroys shareholder value at sub-book prices

Issuance of Capital StockFree Cash Flow TTMP/B Ratio

Bull vs Bear Balance

AI-generated sentiment analysis based on fundamental metrics and market conditions.

20%

Leverage PPCB's top insights and create a custom strategy based on them in seconds. Our AI editor does it all — in one click.

Take Me to The Editor

Forward Thesis

Imminent financing event required within 3-6 months or operational shutdown

3-12mhigh

Cash runway ~3 months at current burn
No revenue path visible
Equity issuance is sole funding mechanism

602K cash vs -2.1M FCF TTM3.3M raised via dilution TTMZero revenue, -61.7M operating loss

Valuation Context

Caveats

Public Strategies Rankings

See how Propanc Biopharma Inc ranks across different investment strategies.

Leverage PPCB's top insights and create a custom strategy in seconds. Our AI editor does it all — in one click.

PPCB Fundamentals

Manufacturing → Chemical Manufacturing

Metric	Value	YoY Growth	Industry Percentile
Market Cap	$1.56M		—
Enterprise Value	$1.65M		—
P/E Ratio	0.00		—
Total Revenue - TTM	$0		—
Earnings Per Share (diluted) - TTM	$52.11		—
Operating Margin - TTM	0%	0.0%	—
Net Margin - TTM	0%	0.0%	—
Free Cash Flow - TTM	$-3.13M		—
Return on Common Equity - TTM	0%		—
Beta 5Y (Monthly)	unknown		—

PPCB Dividend History

No dividends

PPCB Stock Splits

6 stock splits

01/29/2560000:1 split

05/23/231000:1 split

11/19/201000:1 split

06/24/19500:1 split

04/20/17250:1 split

04/07/17250:1 split

PPCB SEC Filings

Filing Date	Report Date	Report Type	Filing Link
02/17/26	12/31/25	10-Q	0001493152-26-007052
11/14/25	09/30/25	10-Q	0001493152-25-023213
09/29/25	06/30/25	10-K	0001493152-25-016069
05/15/25	03/31/25	10-Q	0001641172-25-010798
02/14/25	12/31/24	10-Q	0001493152-25-006697
11/14/24	09/30/24	10-Q	0001493152-24-045664
09/30/24	06/30/24	10-K	0001493152-24-038815
05/15/24	03/31/24	10-Q	0001493152-24-019940
02/20/24	12/31/23	10-Q	0001493152-24-007191
11/14/23	09/30/23	10-Q	0001493152-23-040980
09/28/23	06/30/23	10-K	0001493152-23-034632
05/15/23	03/31/23	10-Q	0001493152-23-017346
02/10/23	12/31/22	10-Q	0001493152-23-004150
11/14/22	09/30/22	10-Q	0001493152-22-032116
09/28/22	06/30/22	10-K	0001493152-22-027033
05/16/22	03/31/22	10-Q	0001493152-22-013577
02/14/22	12/31/21	10-Q	0001493152-22-004382
11/12/21	09/30/21	10-Q	0001493152-21-028221
09/28/21	06/30/21	10-K	0001493152-21-023973
05/14/21	03/31/21	10-Q	0001493152-21-011560
02/12/21	12/31/20	10-Q	0001493152-21-003609
11/16/20	09/30/20	10-Q	0001493152-20-021528
10/01/20	06/30/20	10-K	0001493152-20-018726
05/15/20	03/31/20	10-Q	0001493152-20-009146
02/14/20	12/31/19	10-Q	0001493152-20-002576
11/14/19	09/30/19	10-Q	0001493152-19-017566
10/15/19	06/30/19	10-K	0001493152-19-015529
05/15/19	03/31/19	10-Q	0001493152-19-007459
02/14/19	12/31/18	10-Q	0001493152-19-002072
11/13/18	09/30/18	10-Q	0001493152-18-015599
09/17/18	06/30/18	10-K	0001493152-18-013392
05/10/18	03/31/18	10-Q	0001493152-18-006584
02/09/18	12/31/17	10-Q	0001493152-18-001696
11/09/17	09/30/17	10-Q	0001493152-17-012713
09/28/17	06/30/17	10-K	0001493152-17-011027
05/08/17	03/31/17	10-Q	0001493152-17-004870
02/14/17	12/31/16	10-Q	0001144204-17-008493
11/10/16	09/30/16	10-Q	0001144204-16-133411
09/28/16	06/30/16	10-K	0001144204-16-125808
05/16/16	03/31/16	10-Q	0001144204-16-102344
02/16/16	12/31/15	10-Q	0001144204-16-082302
11/16/15	09/30/15	10-Q	0001144204-15-065865
09/30/15	06/30/15	10-K	0001144204-15-057458
05/15/15	03/31/15	10-Q	0001144204-15-031499
02/17/15	12/31/14	10-Q	0001144204-15-009533
11/19/14	09/30/14	10-Q	0001144204-14-069836
10/14/14	06/30/14	10-K	0001144204-14-060984
05/20/14	03/31/14	10-Q	0001354488-14-002818
02/14/14	12/31/13	10-Q	0001354488-14-000725
11/14/13	09/30/13	10-Q	0001354488-13-006349
10/15/13	06/30/13	10-K	0001354488-13-005698
05/20/13	03/31/13	10-Q	0001354488-13-003018
02/20/13	12/31/12	10-Q	0001354488-13-000756
11/19/12	09/30/12	10-Q	0001354488-12-006039
10/15/12	06/30/12	10-K	0001354488-12-005291
05/21/12	03/31/12	10-Q	0001354488-12-002768
02/21/12	12/31/11	10-Q	0001354488-12-000758
11/19/12	09/30/11	10-Q	0001354488-12-006039
10/15/12	06/30/11	10-K	0001354488-12-005291
05/21/12	03/31/11	10-Q	0001354488-12-002768
02/21/12	12/31/10	10-Q	0001354488-12-000758